Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Becton, Dickinson and Company

BDX

HIGHLY FAVORABLE

May 22, 2026

Research Conclusion

BUY at ~$143. BDX is a wide-moat medical device franchise trading at 9.4x FY2026E adj EPS—an orphan multiple, ~40% discount to peer medical device average (Medtronic 16x, Boston Scientific 22x, Stryker 25x). The discount reflects post-spinoff uncertainty, interim CFO status, and Alaris ramp uncertainty—all recoverable, not structural. Three independent growth catalysts are in motion: Alaris consent decree resolved April 2025 with 4-year pent-up demand; GLP-1 BioPharma syringes targeting $1B by FY2030; Edwards Critical Care integration. ROIC of 11.8% vs. WACC of 7.5% confirms genuine value creation (+4.3pp spread). PWFV ~$220-236 (+54-65%); base case $240 (+68%); bear case $165 (+15%). One of the cleanest risk/reward setups in the S&P 500.

Company Overview & Moat Assessment

Becton Dickinson is a global medical device manufacturer with ~$19.2B revenue (FY2026E continuing operations post-Life Sciences spin) across four segments: BD Medical (medication delivery and management, including the Alaris infusion pump system; ~45%), BD Interventional (surgical, peripheral vascular, urology including PureWick; ~30%), BD BioPharma Systems (prefilled syringes for biologics including GLP-1 drugs; ~10%), and Advanced Patient Monitoring (Edwards Critical Care; ~15%). BDX shipped over 50 billion medical devices in FY2025 from 50+ manufacturing facilities in 45 countries. The company is in a multi-year portfolio transition phase: Embecta spun in 2022; Edwards Critical Care acquired September 2024 ($4.2B); Life Sciences spun February 2026; the four-year Alaris FDA consent decree fully resolved April 2025. Current adj EPS guidance is ~$15.20 FY2026; the company carries ~$18B net debt (~3.5x ND/EBITDA); FCF ~$2.7B FY2026E.

▲ Bull Case

  • ◆P/E re-rating from 9.4x toward peer 14-16x with no EPS change required: A simple re-rating to the low end of medical device peer multiples—even applying a 25% discount to Medtronic's 16x—delivers $235-260 (+64-82%); reaching MDT parity (16x FY2027E) delivers $268 (+87%); approaching Boston Scientific's 22x is unrealistic but possible in bull tail
  • ◆Three simultaneous catalysts compound on FY2026-FY2027 results: Alaris pent-up demand release ($300-400M incremental revenue), GLP-1 BioPharma reaching $1B FY2030 trajectory, Edwards APM contributing $400M+ EBITDA—combined EBITDA tailwind of $700M-1B over 2 years drives adj EPS to $20+ by FY2028
  • ◆D&A burn-off provides $0.50-0.75/yr mechanical GAAP EPS tailwind: $2.3B annual D&A from Bard/CareFusion intangibles declining $200-300M/yr over 5+ years—GAAP EPS grows ~13%/yr CAGR vs. adj +10%/yr; over a 5-yr hold, the GAAP-adj gap closes meaningfully, supporting valuation re-rating

▼ Bear Case

  • ◆Alaris recovery is slower and less complete than modeled: Hospitals that switched to ICU Medical or B. Braun during the 4-year consent decree maintain those relationships; competitive switching is sticky in medical devices; share recovery may be only 50-60% of FY2020 baseline
  • ◆Oral GLP-1 formulations capture 30%+ injectable share by FY2028-FY2029: Pfizer's danuglipron and Novo's oral semaglutide could approve and reimburse before FY2028; BDX BioPharma syringe revenue stalls at $700-800M instead of $1B; the GLP-1 premium narrative unwinds
  • ◆Edwards Critical Care integration disappoints; goodwill impairment risk: Closed-loop monitoring strategy fails to resonate with hospitals already invested in Phillips/GE; $1.5-2B impairment charge in FY2027 echoes the Hillrom/BAX failure pattern; signals capital allocation problem
Primary Debate on Wall Street

“The debate is whether BDX is a stagnant ex-growth mature medical device company (justifying 10-11x P/E) or a high-quality multi-catalyst compounder in transition (justifying 14-16x). Bulls argue: New BD post-spin is a higher-growth portfolio (+5-6% vs. legacy +3-4%); Alaris + GLP-1 + Edwards are three independent growth vectors; D&A burn-off provides mechanical EPS tailwind; the +4.3pp ROIC-WACC spread is durable value creation. Bears argue: BDX has been a 'value trap' for 18+ months; multiple compression from 18x to 9.4x reflects genuine deterioration; the $18B leverage and interim CFO create ongoing uncertainty; portfolio transition fatigue. The resolution likely comes from Q3-Q4 FY2026 results: any single quarter showing Alaris revenue acceleration + GLP-1 BioPharma breakout + permanent CFO appointment could initiate the re-rating.”

Top Catalysts
  • ◆Q3 FY2026 earnings: Alaris metrics (July 2026)—Connected Care revenue acceleration; pump installation cadence; ADD on weakness toward $150
  • ◆Permanent CFO appointment (Q2-Q3 2026)—Removes governance overhang; lender confidence rises
  • ◆FY2026 Investor Day: GLP-1 breakout (Late 2026)—Quantified BioPharma trajectory to $1B; potential re-rating trigger
  • ◆BD Excellence margin expansion >50bps (Each FY)—EBITDA tailwind; consistent execution signal
  • ◆Net Debt/EBITDA below 3.0x (Mid-FY2027)—Credit rating upgrade potential; buyback acceleration unlocked
Top Risks
  • ◆Alaris recovery slower than modeled (MEDIUM probability, MEDIUM impact)—Monitor Connected Care quarterly revenue YoY; switching to ICU Medical/B. Braun may be sticky
  • ◆Oral GLP-1 formulations approved and reimbursed broadly by FY2027-2028 (MEDIUM probability, MEDIUM-HIGH impact)—Pfizer/Novo approvals disrupt BioPharma growth; $1B trajectory at risk
  • ◆Edwards Critical Care integration disappoints; goodwill impairment >$1B (LOW-MEDIUM probability, HIGH impact)—Echoes Hillrom/BAX failure; capital allocation questioned
  • ◆New FDA action on Alaris or related products (LOW probability, HIGH impact)—Any 483 letter or warning letter would re-impair moat
  • ◆Permanent CFO unable to be hired or weak candidate (LOW probability, MEDIUM impact)—Extends governance uncertainty; Q2-Q3 2026 critical
  • ◆Refinancing at higher rates (LOW-MEDIUM probability, LOW impact)—Bounded by investment-grade status

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/BDX/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.